| Date | Title | | | Dec 01, 2008 | FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review| May Accelerate First-line Launch by Four Months
SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug
Administration (FDA) has accepted for filing and review, and has granted
priority review status for, the supplemental Biologics License Application
(sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation
therapy for patients with follicular B-cell non-Hodgkin's lymphom... |
|  | | Dec 01, 2008 | Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides| SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, Cell
Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a
conference call to discuss the agreement with Spectrum Pharmaceuticals of
Irvine, California to jointly market and develop Zevalin(R). The call will be
webcast with slides, and the slides are also available for review on CTI's
website, http://www.celltherapeutics.com/... |
| | | Nov 28, 2008 | Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals| SEATTLE, Nov. 28 /PRNewswire-FirstCall/ -- On Monday, December 1, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will
host a conference call to discuss the agreement with Spectrum Pharmaceuticals
of Irvine, California to jointly market and develop Zevalin(R).
Conference Call Numbers
Monday, December 1
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific T... |
| | | Nov 26, 2008 | Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug| - ZEVALIN is Currently FDA Approved for Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma - sBLA for First Line Consolidation Therapy Is Currently Under Review By The FDA - Complements Existing and Potential Oncology Product Portfolios of Both Companies
IRVINE, Calif., and SEATTLE, Nov 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Spectrum
Pharmaceuticals, Inc. (Nasdaq: SPPI) and Cell Therapeutics, Inc.
(Nasdaq: CTIC)(MTA: CTIC) announced today they have entered into an agre... |
| | | Nov 11, 2008 | Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint| Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher
Compared to Standard Chemotherapy
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it achieved the primary efficacy
endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for
patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based
on a preliminary intent to treat efficacy analysis. ... |
| | | Nov 10, 2008 | Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma|
SEATTLE, Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that Clinical Cancer Research has
published in the November 1, 2008 issue the results of a study authored by
Samual Jacobs et al. investigating the use of short-course CHOP-R followed by
Zevalin ([90Y]-ibritumomab tiuxetan) and extended rituximab as first-line
treatment in follicular non-Hodgkin's lymphoma patients. Addition of the
Zevalin therapeu... |
| | | Nov 07, 2008 | Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008| Zevalin(R) on Track for Break-Even in 2008
SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) reported financial results for the quarter ended
September 30, 2008. Total revenues for the quarter were $2.6 million compared
to $20,000 for the third quarter of 2007 due primarily to sales of Zevalin(R)
(Ibritumomab Tiuxetan), a commercial radiopharmaceutical that CTI acquired in
December 2007. Net product sales of Zevalin totale... |
| | | Nov 06, 2008 | Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast| SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management will present at the Rodman & Renshaw 10th
Annual Healthcare Conference on Tuesday, November 11th at 10:45 AM at the New
York Palace Hotel.
The conference will also be webcast live with slides and available for
replay after the presentation. The webcast can be accessed at
http://www.celltherapeutics.com.
Rodman & Renshaw 10th Annual Healthcare Conference
... |
| | | Nov 05, 2008 | Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7| SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- On Friday, November 7, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC) (MTA: CTIC) management team
will host a quarterly conference call to discuss the Company's 2008 third
quarter achievements and financial results.
Conference Call Numbers
Friday, November 7
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-835-3299 (U... |
| | | Nov 03, 2008 | Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial| Novartis notified of data set closing, Top-line results expected in November
SEATTLE, Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has closed the data set for
preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301)
trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell
non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data
... |
| | | Oct 31, 2008 | Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast| SEATTLE, Oct. 31 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management will present at the Oppenheimer & Co. 19th
Annual Healthcare Conference on Monday, November 3rd at 8:00 AM at the
Waldorf-Astoria Hotel.
The conference will also be webcast live with slides and available for
replay after the presentation. The webcast can be accessed at
http://www.celltherapeutics.com.
Oppenheimer & Co. 19th Annual Healthcare Conference
... |
| | | Oct 27, 2008 | Cell Therapeutics, Inc. (CTI) to Present at 7th Annual BIO Investor Forum| SEATTLE, Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management will present at the 7th Annual Biotechnology
Industry Organization (BIO) Investor Forum on Thursday.
The conference will be held October 29-31, 2008, at the Palace Hotel in
San Francisco. CTI will present on Thursday, October 30 at 8:00 a.m. (PT). The
conference will be webcast live with slides and available for replay after the
presentation. The webcast c... |
| | | Oct 22, 2008 | Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes| SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq and MTA: CTIC) today announced that a single
institutional investor shall purchase, for $24.7 million, newly issued 9.66%
Convertible Senior Notes due 2011, with a conversion price of $0.38 per share.
The new Notes would have a $24.7 million initial principal balance and
feature a make-whole provision entitling the holder, upon any conversion of
the Notes, to receive the interest pay... |
| | | Oct 20, 2008 | High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma| Novel Outpatient Regimen Pioneered by Investigators from Tumor Institute in Milan
SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology
has published the results of an innovative study that investigated high (bone
marrow ablative) dose Zevalin(R) ([90Y]-ibritumomab tiuxetan) followed by
autologous stem cell infusions among 30 patients (median age 62 years) with
relapsed/refractory or high ... |
| | | Oct 16, 2008 | Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma| Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results published in Journal of Clinical Oncology
SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology
has published the results of the First-line Indolent Trial (FIT) demonstrating
that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy
after remission induction in previously untreated patients with follicul... |
| | | Oct 13, 2008 | Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences| SEATTLE, Oct. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) has been selected to present at three upcoming investor
conferences. The conferences include the 7th Annual BIO Investor Forum in San
Francisco in October, the 19th Annual Oppenheimer & Co. Healthcare Conference,
and the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference in
November, both in New York City.
The presentations will be webcast live with slides, and ava... |
| | | Oct 10, 2008 | Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter| SEATTLE, Oct 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Company intends to request a
hearing with the NASDAQ Listing Qualifications Panel to present a plan for
regaining compliance with NASDAQ Marketplace Rule 4450(b)(1)(A), which
requires a minimum market value of listed securities of $50 million. CTI
received a Staff Determination Letter from The NASDAQ Stock Market LLC on
October 7, 2008 indica... |
| | | Oct 03, 2008 | Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe| Readies R & D facilities for Ap3ana, CTI's 'personalized medicine' venture
SEATTLE, Oct. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC) announced today that Christina A. Waters, Ph.D., M.B.A., most
recently President and COO of a Tyr Pharma and formerly Director of Scientific
Development at Genomics Institute of the Novartis Research Foundation, has
been named President of CTI Europe. Based in Bresso, Italy, CTI Europe
currently conducts the research and ... |
| | | Oct 02, 2008 | Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy| Approval would make Zevalin only Radioimmunotherapy in U.S. to be Indicated for Use in First-Line Therapy
SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental
Biologics License Application (sBLA) with the U.S. Food and Drug
Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as
consolidation therapy after remission induction in previously untreated
patients with follicul... |
| | | Sep 30, 2008 | Cell Therapeutics Provides Details on Investor & Media Day to be Held in Milan, Italy on Friday, October 3, 2008| SEATTLE, Sept. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) will host an investor and media day in Milan, Italy on
October 3, 2008. The investor day will provide an update from executive
management on key strategic initiatives and regulatory milestones for the
Company. Additionally, Alessandro Gianni, M.D., Director of the School of
Specialization in Medical Oncology at the University of Milan, who has
authored over 300 publications will be a guest ... |
| | | Sep 29, 2008 | Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes| SEATTLE, Sept. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq: CTICD and MTA: CTIC) today announced that a single
institutional investor shall purchase, for $14.2 million, newly issued 15.5%
Convertible Senior Notes due 2012, with a conversion price of $1.27 per share.
The transaction is the result of an amendment of a September 15, 2008
agreement (as amended on September 26, 2008) under which the investor had
purchased $9 million of senior notes ... |
| | | Sep 25, 2008 | Cell Therapeutics Regains Compliance with NASDAQ's Minimum Bid Price Requirement| SEATTLE, Sept. 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTICD and MTA: CTIC) announced today that the Company has received a
letter from The NASDAQ Stock Market confirming that it has regained compliance
with the minimum bid price requirement for continued listing on The NASDAQ
Global Market under Marketplace Rule 4450(a)(5). In the letter, NASDAQ stated
that this matter is now closed.
The Company continues its efforts to regain compliance with NASDAQ
M... |
| | | Sep 22, 2008 | FDA Meeting Provides Green Light for Cell Therapeutics Submission of Supplemental Filing for Zevalin(R) Label Expansion| Supplemental Biologics License Application (sBLA) on track for Q4 Submission
SEATTLE, Sept. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTICD and MTA: CTIC) announced today that following a meeting with
the U.S. Food and Drug Administration (FDA) data from the First-line Indolent
Trial (FIT) would be sufficient to support a submission for a supplemental
Biologics License Application (sBLA). The sBLA will propose a label expansion
to include use of the Zevalin(R... |
| | | Sep 15, 2008 | Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes| Single Institutional Investor Purchases $9MM Convertible Notes
NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
("CTI" or the "Company") (Nasdaq: CTICD, and MTA: CTIC) today announced that a
single institutional investor has agreed to purchase, for $9 million, newly
issued 10% Convertible Senior Notes due 2012, with a conversion price of $1.27
per share. The Company has a put right subject to price, volume and other
requirements exercisable no later than Oc... |
| | | Sep 11, 2008 | Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008| Company Plans to Provide Update on Key Regulatory Milestones
SEATTLE, Sept 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTICD; and MTA: CTIC) announced today that it will host an investor
day in Milan, Italy on October 3, 2008. The investor day will provide an
update from executive management on key strategic initiatives and regulatory
milestones for the Company. The meeting will be an invitation-only event. A
webcast and live telec... |
| | | Sep 06, 2008 | CTI Receives NASDAQ Letter| SEATTLE, Sept. 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTICD; and MTA: CTIC) announced that today, the Company received a
letter from the Listing Qualifications Staff of The NASDAQ Stock Market LLC
indicating that the Company is not in compliance with the $50,000,000 minimum
market value of listed securities requirement set forth in NASDAQ Marketplace
Rule 4450(b)(1)(A). Furthermore, the Company does not comply with NASDAQ
Marketplace Rule 4450(b)(1)(B), whic... |
| | | Aug 25, 2008 | Cell Therapeutics, Inc. Announces Reverse Stock Split| Board of Directors approves 1-for-10 split ratio
SEATTLE, Aug 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced that its Board of Directors has authorized a
1-for-10 reverse split of its common stock. The reverse split will become
effective as of August 31, 2008.
At the Cell Therapeutics Special Meeting in Lieu of Annual Meeting of
Shareholders held on June 19, 2008, shareholders approved a proposal to
authorize t... |
| | | Aug 18, 2008 | Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results| Zevalin(R) net sales of $15 million in 2008 on target; Potential label
expansion could further drive sales
SEATTLE, Aug. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) reported financial results for the quarter ended June
30, 2008. Total revenues for the quarter were $2.9 million compared to $20,000
for the second quarter of 2007 due primarily to sales of Zevalin(R)
(Ibritumomab Tiuxetan), a commercial radiopharmaceutical that... |
| | | Aug 14, 2008 | Cell Therapeutics, Inc. (CTI) to Report 2008 Second Quarter Financial Results on August 18| SEATTLE, Aug. 14 /PRNewswire-FirstCall/ -- On Monday, August 18, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific members of Cell
Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC; MTA) management team will host a
quarterly conference call to discuss the Company's 2008 second quarter
achievements and financial results.
Conference Call Numbers
Monday, August 18
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-800-218-8862 (US Partic... |
| | | Aug 12, 2008 | Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma| Potential for data analysis early 2009
SEATTLE, Aug. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.'s (CTI)
(Nasdaq: CTIC; MTA) subsidiary Systems Medicine (SM) announced today that
planned enrollment is complete in the European Organization for Research and
Treatment of Cancer (EORTC) randomized phase II clinical trial of brostallicin
in patients with newly diagnosed advanced or metastatic soft tissue sarcoma
who have had no prior chemotherapy. The primary en... |
| | | Aug 05, 2008 | Craig W. Philips Takes Helm at CTI| President assumes day to day commercial and development responsibilities
SEATTLE, Aug 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc.
(the "Company") (Nasdaq: CTIC; MTA) t announced that Craig W. Philips has
assumed his role as CTI's new President, and will concentrate on managing the
company's drug development and commercial operations. Most recently, Philips
was Vice President and General Manager of Bayer Healthcare Oncology. He will
report to CTI's... |
| | | Jul 29, 2008 | Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit| SEATTLE, July 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(the "Company") (Nasdaq: CTIC; MTA) today announced that it has entered into
an equity line of credit agreement with Midsummer Investment, Ltd. for the
sale of up to $12 million of common stock over time (the "Agreement"). The
stock would be issued upon exercise of a warrant pursuant to the terms of the
Agreement.
The Company has the right to raise cash under the Agreement for shares of
the Company's common stock ... |
| | | Jul 24, 2008 | Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants| Investor Also Agrees to Increase Original Warrant Amount by an Additional
$44.5 million
SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) today announced that a single institutional investor
has agreed to purchase, for $44.5 million, newly issued 18.33% Convertible
Senior Notes due 2011, with a conversion price of $0.79 per share, and a
warrant to purchase approximately 28.2 million shares of common stock with an... |
| | | Jul 22, 2008 | CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)| September meeting to focus on use of Zevalin as consolidation therapy after
remission induction in previously untreated patients with follicular lymphoma
SEATTLE, July 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Company has scheduled a
meeting with the U.S. Food and Drug Administration (FDA) in September to
discuss the possibility of filing a supplemental Biologics License Application
(sBLA) for use of Zevalin(R) ([90Y]-ib... |
| | | Jul 15, 2008 | 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto| SEATTLE, July 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced that Congress today passed the Medicare
Improvements for Patients and Providers Act of 2008, which includes an
18-month extension of the 2007 reimbursement rate for radioimmunotherapies
such as Zevalin(R) (Ibritumomab Tiuxetan), overriding President Bush's veto.
The bill was originally passed by the U.S. House of Representatives on
June 24, 2008 and by the U.S. Senate on July 9... |
| | | Jul 09, 2008 | Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months| SEATTLE, July 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced that the Medicare Improvements for Patients
and Providers Act of 2008, as passed by the U.S. House of Representatives on
June 24, 2008 and the U.S. Senate on July 9, 2008, would continue the 2007
reimbursement methodology for therapeutic radioimmunotherapies for an
additional 18 months with a start date of July 1, 2008. In December, Congress
froze reimbursement rates at the 2007 lev... |
| | | Jul 07, 2008 | Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology| Results are basis for CTI's Marketing Authorization Application currently
under review by the EMEA
SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) today announced the publication of results from its
randomized phase III trial comparing OPAXIO(TM) (paclitaxel poliglumex,
CT-2103) with gemcitabine or vinorelbine for the treatment of PS 2
(performance status 2) patients with previously untreated non-small cell lung
... |
| | | Jun 20, 2008 | Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders| Proposals approved by more than 95 percent of votes cast
SEATTLE, June 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) held a Special Meeting in lieu of the Annual Meeting of
Shareholders on Thursday, June 19, 2008 at its headquarters in Seattle. At the
meeting, shareholders approved all matters with more than 95 percent of votes
cast at the meeting voting in favor of each of the items proposed in the
Company's Proxy Statement, including the re... |
| | | Jun 18, 2008 | Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data| SEATTLE, June 18 /PRNewswire-FirstCall/ -- On Wednesday, June 18, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC; MTA) management team will host
a conference call to discuss agreement with Bayer Schering Pharma for access
to Phase III Zevalin(R) FIT Trial data.
Conference Call Numbers
Wednesday, June 18
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-800-240-7305... |
| | | Jun 18, 2008 | CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application| Access to data may provide potential for label expansion in the U.S.
SEATTLE, June 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) announced today an agreement with Bayer Schering Pharma to
gain access to Bayer's phase III Zevalin(R) ([90Y]-ibritumomab tiuxetan)
First-line Indolent Trial, FIT data. CTI expects that the data from the trial
will be appropriate for CTI to begin discussions with the U.S. Food and Drug
Administration (FDA) regarding the p... |
| | | Jun 16, 2008 | Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt| SEATTLE, June 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced the Company has repaid the remaining
balance, including accrued interest, of its 2008 Convertible Notes which
reached maturity on June 15, 2008 through a cash payment of approximately
$11.0 million. The Company currently has no debt maturing before Q3 2010.
"Retiring this last piece of current debt provides the Company more than
24 months to deliver our sales and product ... |
| | | Jun 13, 2008 | Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008| SEATTLE, June 13 /PRNewswire-FirstCall/ -- On Thursday, June 19, 2008, at
7:00 PM Central European Time/1:00 PM Eastern Time/10:00 AM Pacific Time
members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management
team will host a Special Meeting in lieu of the Annual Meeting of Shareholders
at its Seattle headquarters located at 501 Elliott Ave. West, Seattle, WA
98119. The meeting will be webcast live on CTI's website at
http://www.CellTherapeutics.com and archived for repl... |
| | | Jun 12, 2008 | Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor| SEATTLE, June 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq and MTA: CTIC) today announced that a single institutional investor
has agreed to purchase, for $23 million, newly issued 15% Convertible Senior
Notes due 2011, with an initial conversion price of $0.79 per share, and a
warrant to purchase approximately 14.6 million shares of common stock with an
exercise price of $0.95 per share.
This transaction constitutes a partial exercise of a previously granted
warra... |
| | | Jun 09, 2008 | Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma| Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78 percent progression-free survival rates in patients receiving radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this patient population
LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral
presentation today at the 10th International Conference on Malignant Lymphoma
in Lugano, Switzerland, Paul A. Hamlin, M.... |
| | | Jun 05, 2008 | Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma| Results of phase I/II study highlighted in oral presentation at conference on
malignant lymphoma
LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th
International Conference on Malignant Lymphoma in Lugano, Switzerland data
were presented from a phase I/II investigator-sponsored clinical trial of
Yttrium-90 Ibritumomab Tiuxetan (90Y-Zevalin) combined with the novel expanded
porphyrin motexafin gadolinium (MGd). The greatest benefit of this
i... |
| | | Jun 03, 2008 | Paclitaxel Poliglumex (OPAXIO(TM))/Capecitabine Regimen Well Tolerated and Active in Metastatic Breast Cancer| Results of phase II investigator-sponsored trial presented at ASCO show Investigational regimen active with 42 percent objective tumor responses
CHICAGO, June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- At the 2008 Annual Meeting of
the American Society of Clinical Oncology (ASCO), data were presented from a
phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO(TM),
CT-2103) in combination with capecitabine in first-line treatment of patients
with metastatic br... |
| | | Jun 02, 2008 | Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma| CHICAGO, June 2 /PRNewswire-FirstCall/ -- At the 44th Annual Meeting of
the American Society of Clinical Oncology (ASCO), two studies were presented
investigating the potential utility of Zevalin(R) (Ibritumomab Tiuxetan)
radioimmunotherapy as replacement for external beam radiations or supplement
to high-dose chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL).
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) markets Zevalin in the
United States.
"These two studies add... |
| | | May 27, 2008 | Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting| SEATTLE, May 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced that the following presentations will
be made on its product Zevalin(R) (Ibritumomab Tiuxetan) and its development
product OPAXIO(TM) (paclitaxel poliglumex, formerly XYOTAX(TM)) at the 44th
American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 through
June 3, 2008, in Chicago.
Date Time Poster # Title
(Abstract#)... |
| | | May 15, 2008 | Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference| SEATTLE, May 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) management will present at the Rodman & Renshaw 5th
Annual Global Healthcare Conference on Monday, May 19th at 9:40 AM in the
Atlantique Salon, Meridional at the Le Meridien Beach Plaza Hotel in Monaco.
The presentation will also be webcast live with slides, and available for
replay after the presentation. The webcast can be accessed at
http://www.celltherapeutics.com.
Rodma... |
| | | May 08, 2008 | Zevalin Revenues Lead Cell Therapeutics, Inc.'s First Quarter 2008 Financial Results| Company resumes commercial operations with first product sales since 2005
SEATTLE, May 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) reported financial results for the quarter ended
March 31, 2008. Total revenues for the quarter were $3.4 million compared to
$20,000 for the first quarter of 2007. Gross product sales of Zevalin(R)
(Ibritumomab Tiuxetan) reached $3.8 million in the first quarter of 2008.
Total operating expenses increased to $28.4... |
| | | May 05, 2008 | Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8| SEATTLE, May 5 /PRNewswire-FirstCall/ -- On Thursday, May 8, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific members of Cell
Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC; MTA) management team will host a
quarterly conference call to discuss the company's 2008 first quarter
achievements and financial results.
Conference Call Numbers
Thursday, May 8
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
1-877-835-3295 (US Participants)... |
| | | May 05, 2008 | European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug| Important step toward commercialization: CTI selects OPAXIO(TM) as global
brand name to replace XYOTAX(TM)
SEATTLE, May 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) today announced that it received a positive opinion from
the European Medicines Agency (EMEA) for the brand name OPAXIO(TM) (paclitaxel
poliglumex), which replaces XYOTAX(TM) as the brand name.
"We are pleased the EMEA has provided a favorable review of the OPA... |
| | | Apr 30, 2008 | Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor| Transaction also provides the Company and investor an option to sell or purchase additional $67.5 million in securities
SEATTLE, April 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. ("CTI"
or the "Company") (Nasdaq: CTIC; MTA) today announced that it has entered into
agreements to sell units of securities for approximately $64.5 million,
including new Series E Convertible Preferred Stock (the "Preferred Stock"),
13.5% Convertible Senior Notes due 2014 ... |
| | | Apr 24, 2008 | Veteran Drug Industry Executive to Become President of CTI| New Leadership Completes CTI's Transformation to Commercial Operating Business
SEATTLE, April 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(Nasdaq: CTIC; MTAX) today announced that Craig W. Philips, most recently Vice
President and General Manager of Bayer Healthcare Oncology, has been named
President of CTI with direct responsibilities for all Development and
Commercial Operations, effective August 1, 2008. Philips' responsibilities
will center on strategic management of onco... |
| | | Apr 18, 2008 | Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement| SEATTLE, April 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC) today announced that on April 16, 2008 it received a
letter from The NASDAQ Stock Market indicating that for the last 30
consecutive business days the bid price of its common stock has closed below
the minimum $1.00 per share requirement for continued inclusion under
Marketplace Rule 4450(a)(5). This notification has no immediate effect on the
listing of or the ab... |
| | | Apr 15, 2008 | Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling| Data presented at AACR 2008
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a
wholly owned subsidiary of Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC), presented data from a preclinical study demonstrating
that the Company's experimental drug candidate, brostallicin, killed colon and
ovarian cancer cells regardless of their p53 status. The study, conducted by
Cristina Geroni, Ph.D., et al of Nerviano Medical Sciences in Milan, I... |
| | | Apr 14, 2008 | New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit| Cancer drug development guided by genomics
SAN DIEGO, April 14 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a
wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC), presented data from a preclinical study identifying
the genetic markers in patients more likely to respond to treatment with the
experimental drug, brostallicin, at the 2008 American Association for Cancer
Research (AACR) annual meeting. These findings will be used to guide future
development... |
| | | Apr 02, 2008 | European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review| SEATTLE, April 2, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
(CTI) (Nasdaq: CTIC; MTA) today announced that the European Medicines Agency
(EMEA) has accepted for review CTI's Marketing Authorization Application (MAA)
for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of
patients with non-small cell lung cancer (NSCLC) with ECOG (Eastern
Cooperative Oncology Group) performance status 2 (PS2). CTI submitted the MAA
at the beginning of March. The validati... |
| | | Mar 28, 2008 | Cell Therapeutics, Inc. Announces Filing of Form 10-K| SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced that the filing of its annual report on
Form 10-K for the year ended December 31, 2007 has now been timely completed.
This filing is available for review on CTI's Web site at
http://www.CellTherapeutics.com or on the Securities and Exchange Commission's
Web site at http://www.sec.gov.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also
announced that its i... |
| | | Mar 25, 2008 | Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL| Potential NDA Submission in 2009
SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) announced today that enrollment is complete in the phase
III EXTEND (PIX301) clinical trial of pixantrone (BBR2278) for patients with
relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL). An analysis of the
data is expected in the second half of 2008. Based on prior discussions with
the U.S. Food and Drug Administration (FDA) the da... |
| | | Mar 18, 2008 | Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast| SEATTLE, March 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTAX) management will present at the 7th Annual WBBA Invest
Northwest Conference on Tuesday, March 18 at 9:00 AM Pacific Time (PT) in the
Bay Auditorium of the Bell Harbor Conference Center.
The presentation will also be webcast live with slides, and available for
replay after the presentation. The webcast can be accessed at
www.celltherapeutics.com.
WBBA Invest Northw... |
| | | Mar 17, 2008 | Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma| Phase II study of investigational regimen demonstrates important role of radioimmunotherapy in converting partial remissions to complete remissions and inducing a high rate of molecular remissions
SEATTLE, March 17, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) today announced that patients with previously untreated
follicular non-Hodgkin's lymphoma (NHL) treated with fludarabine and
mitoxantrone, followed by administration of Ze... |
| | | Mar 13, 2008 | Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results|
Restructured majority of convertible notes due June 2008
Reduced net operating expenses going forward
Projects Zevalin(R) net sales revenues of $15 million in 2008
SEATTLE, March 13 /PRNewswire-FirstCall/ -- Seattle-Cell Therapeutics,
Inc. (CTI) (Nasdaq: CTIC; MTA) today reported recent accomplishments and
financial results for the quarter and twelve months ended December 31, 2007.
Recent Events
Announced completion of Zevalin(R)... |
| | | Mar 10, 2008 | Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference| SEATTLE, March 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTAX) management will present at the 7th Annual WBBA Invest
Northwest Conference on Tuesday, March 18th at 9:00 AM in the Bay Auditorium
of the Bell Harbor Conference Center.
The presentation will also be webcast live with slides, and available for
replay after the presentation. The webcast can be accessed at
www.cticseattle.com.
WBBA Invest Northwest Conference
CTI Presentation: ... |
| | | Mar 07, 2008 | Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13| SEATTLE, March 7 /PRNewswire-FirstCall/ -- On Thursday, March 13, 2008, at
8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific members of Cell
Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC; MTAX) management team will host a
quarterly conference call to discuss the company's 2007 fourth quarter
achievements and year-end financial results.
Conference Call Numbers
Thursday, March 13
8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific Time
1-800-... |
| | | Mar 06, 2008 | Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis| Preclinical profile and potential for lower cardiac toxicity drives
investigator interest
SEATTLE, March 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that its investigational drug
pixantrone will be studied in a multicenter phase I/II trial initiated by the
Fondation Charcot Stichting, in Brussels, Belgium, which sponsors a consortium
of centers involved in studying new therapies for the treatment for ... |
| | | Mar 05, 2008 | CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma| European phase II study of 20 patients reported in Annals of Oncology
SEATTLE, March 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq: CTIC; MTA) today announced the publication, by two European
institutions, of results of a limited phase II study of CHOP chemotherapy
(cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by
administration of Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60
years of age or older) with previously untreated di... |
| | | Mar 04, 2008 | Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones| SEATTLE, March 4 /PRNewswire-FirstCall/ -- On Wednesday, March 5, 2008, at
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time members of
Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC and MTAX: CTIC) management team
will host a conference call to discuss the company's recent transactions
targeting cleaning up the capital structure, and upcoming product and sales
milestones.
Conference Call Numbers
Wednesday, ... |
| | | Mar 04, 2008 | Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)| XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer indication
SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that it submitted a Marketing
Authorization Application (MAA) to the European Medicines Agency (E |
|
|
